Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers

Urologic Oncology: Seminars and Original Investigations

Volumn 34, Issue 7, 2016, Pages 292.e9-292.e16

  Malentacchi, Francesca ^a   Vinci, Serena ^a   Melina, Alessandro Della ^b   Kuncova, Jitka ^c   Villari, Donata ^a   Nesi, Gabriella ^d   Selli, Cesare ^e   Orlando, Claudio ^a   Pazzagli, Mario ^a   Pinzani, Pamela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Division of Urology   (Italy)

^c SS Giacomo e Cristoforo hospital   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

Carbonic anhydrase IX (CAIX) mRNA; Liquid biopsy; Urine; Urogenital cancer

Indexed keywords

CARBONATE DEHYDRATASE IX; MESSENGER RNA; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA SPLICING; SENSITIVITY AND SPECIFICITY; URINE SEDIMENT; UROGENITAL TRACT CANCER; ALTERNATIVE RNA SPLICING; BLADDER TUMOR; CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; GENETICS; KIDNEY TUMOR; PROSTATE TUMOR;

ALTERNATIVE SPLICING; BIOMARKERS, TUMOR; CARBONIC ANHYDRASE IX; CASE-CONTROL STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 84962547852     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2016.02.017     Document Type: Article

References (30)

1. Eichelberg C., Junker K., Ljungberg B., Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009, 55:851-863.
2. Jamaspishvili T., Kral M., Khomeriki I., Student V., Kolar Z., Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 2010, 13:12-19.
3. Urquidi V., Goodison S., Kim J., Chang M., Dai Y., Rosser C.J. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology 2012, 79:1185.e1-1185.e6.
4. Bryzgunova O.E., Skvortsova T.E., Kolesnikova E.V., Starikov A.V., Rykova E.Y., Vlassov V.V., et al. Isolation and comparative study of cell-free nucleic acids from human urine. Ann NY Acad Sci 2006, 1075:334-340.
5. Ralla B., Stephan C., Meller S., Dietrich D., Kristiansen G., Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci 2014, 51:200-231.
6. Gieling R.G., Williams K.J. Carbonic anhydrase IX as a target for metastatic disease. Bioorg Med Chem 2013, 21:1470-1476.
7. Muselaers C.H., Stillbroer A.B., Desar I.M., Broers-Sonderen M.J., van Herpen C.M., de Weijert M.C., et al. Tyrosine kinase inhibitor sorafenib decreases 111-In-gerentuximab uptake in patients with clear cell renal cell carcinoma. J Nucl Med 2014, 55:242-247.
8. Zavada J., Zavadova Z., Zat'ovicova M., Hyrsl L., Kawaciuk I. Soluble form of carbonic anhydrase IX (CAIX) in the serum and urine of renal carcinoma patients. Br J Cancer 2003, 89:1067-1071.
9. Barathova M., Takacova M., Holotnakova T., Gibadulinova A., Ohradanova A., Zatovicova M., et al. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumor phenotype. Br J Cancer 2008, 98:129-136.
10. Takacova M., Bartosova M., Skvarkova L., Zatovicova M., Vidlickova I., Csaderova L., et al. Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol Lett 2013, 5:191-197.
11. Pena C., Lathia C., Shan M., Escudier B., Bukowski R.M. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results for sorafenib phase III treatment approached in renal cancer global evaluation trial. Clin Cancer Res 2010, 16:4853-4863.
12. 111In-cG250 imaging. J. Nucl Med 2012, 53:82-89.
13. Stillebroer A.B., Mulders P.F.A., Booerman O.C., Oyen W.J.G., Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010, 58:75-83.
14. Kock L., Mahner S., Choschzick M., Eulenburg C., Milde-Langosch K., Schwarz J., et al. Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer. Int Gynecol Cancer 2011, 21:141-148.
15. Malentacchi F., Vinci S., Della Melina A., Kuncova J., Villari D., Giannarini G., et al. Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments. Urol Oncol 2012, 30:278-284.
16. Sauter G., Algaba F., Amin M., Busch C., Cheville J., Gasser T., et al. Tumours of the urinary system: non-invasive urothelial neoplasias. WHO Classification of Tumors of the Urinary System and Male Genital Organs 2004, 29-34. IARCC Press, Lyon. J.N. Eble, G. Sauter, E. Jl, I. Sesterhenn (Eds.).
17. Sobin L.H., Gospodarowicz M.K., Wittekind C. TNM Classification of Malignant Tumors 2009, Wiley-Blackwell, Chichester, West Sussex, UK; Hoboken, NJ. 7th ed.
18. Bostwick D.G., Foster C.S., Algaba F., Hutter R.V.P., Montironi R., Mostofi F.K. Prostate cancer. Second International Consultation on Prostate Cancer, Co-Sponsored by WHO an UIC 2000, Plymbridge Distributors Ltd., London. G. Murphy, L. Denis, K. S, A. Parti, L.P. Denis (Eds.).
19. Malentacchi F., Simi L., Nannelli C., Andreani M., Janni A., Pastorekova S., et al. Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer. Lung Cancer 2009, 64:271-276.
20. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
21. Gasparini G., Bonoldi E., Viale G., Verderio P., Boracchi P., Pannizzoni G.A., et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996, 69:205-211.
22. Uroquidi V., Rosser C.J., Gooddison S. Molecular diagnostic trends in urological caner: biomarkers for non-invasive diagnosis. Curr Med Chem 2013, 19:2653-2663.
23. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014, 32:579-587.
24. Warren A.D., Kwong G.A., Wood D.K., Lin K.Y., Bathia S.N. Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics. Proc Natl Acad Sci U S A 2014, 111:3671-3676.
25. Rosser C.J., Dai Y., Miyake M., Zhang J., Goodison S. Simultaneous multi-analyte urinary protein assay for bladder cancer detection. BMC Biotechnol 2014, 14:1-6.
26. Hessels D., Schalken J.A. Urinary biomarkers for prostate cancer: a review. Asian J Androl 2013, 15:333-339.
27. Müller V., Riethdorf S., Rack B., Janni W., Fasching P.A., Solomayer E., et al. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res 2011, 13:R71.
28. Fidan E., Mentese A., Ozdemir F., Deger O., Kavgaci H., Caner Karahan S., et al. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. Med Oncol 2013, 30:540.
29. Stewart D.J., Nunez M.I., Behrens C., Liu D., Lin Y.H., Lee J.J., et al. Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol 2014, 9:675-684.
30. Niemelä A.M., Hynninen P., Mecklin J.P., Kuopio T., Kokko A., Aaltonene L., et al. Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:1760-1765.